Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,234.6
-19.4 (-0.60%)

 

  • STI Straits Times Index
    3,234.6
    -19.4 (-0.60%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,574.4
    -3.5 (-0.22%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    27,909.1
    -431.9 (-1.52%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,976.5
    -84.2 (-2.75%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    23,795.4
    -235.9 (-0.98%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,249.2
    15.8 (0.25%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,246.1
    -21.1 (-0.93%)
    Index delayed 20 minutes
  • XAO XAO
    7,199.0
    -50.0 (-0.69%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,734.1M
  • Value: 1,390.5M
  • Rise: 93
  • Fall: 228
  • Unch: 497

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Reenova Investment^0.003+0.001
Medtecs Intl0.105+0.007
Ntegrator Intl0.015-
Golden Agri-Res0.225-0.005
Rex Intl0.174-0.014
AusGroup^0.039-0.005
YZJ Shipbldg SGD1.060-0.030
OEL0.024-0.005
Singtel3.340+0.060
Jiutian Chemical0.021-0.001

World Indices

World Indices
Name Last Change
Nasdaq 9,383.8 +13.0
HSI 27,909.1 -431.9
HSCEI 10,952.2 -222.5
Jakarta 6,249.2 +15.8
Nikkei 225 23,795.4 -235.9
SSE Comp 2,976.5 -84.2
Shanghai A 3,118.9 -88.2
Shanghai B 248.6 -8.9
PSE Comp 0.0
KOSPI 2,246.1 -21.1

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

JOUNCE THERAPEUTICS INC JOUNCE THERAPEUTICS INC
Updated on 22 Jan 2020 (End of trading day)
Last (USD): 6.895 Change: -0.295 High: 7.330 Remarks: -
Change (%): -4.10 Low: 6.850
Open 7.190 Yesterday's Close 7.1899999999999995
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 293,096 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a -0.82395 Trailing EPS (USD) e 2.33080 NAV (USD) b 5.7603
PE a - Trailing PE f 2.958 Price / NAV b 1.1970
Dividend (USD) d - Cash In Hand (USD) g 1.9983 Issued & Paid-up Shares c 33,229,000
Dividend Yield (%) d - Price / Cash In Hand g 3.450 Treasury Shares h -
Beta - 75 Daysi 1.410 R-Squared - 75 Days(%)i 0.01 Market Cap (M) 229.114
Beta - 500 Daysi 0.054 R-Squared - 500 Days (%)i 0.02 Enterprise Value (M) 73.769
Piotroski F Score 1 Exchange Code JNCE Par Value ( $ ) n.a.
52 Weeks Volatility (%) 81.82 Free Float (%) 47.0
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 07 Nov 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 16 Mar 2017.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference JOUNCE THERAPEUTICS INC NASDAQ 229.114 - 2.958 1.1970 -
Industry Biotechnology NASDAQ 2,401.036 380.284 92.382 5.9820 0.736
Local Peer AMGEN INC NASDAQ 140,673.062 16.759 17.438 12.8739 2.363
Local Peer GILEAD SCIENCES INC NASDAQ 80,248.465 14.711 29.799 3.8948 3.642
Local Peer VERTEX PHARMACEUTICAL NASDAQ 60,329.961 28.778 28.142 11.4840 -
Local Peer BIOGEN INC NASDAQ 51,985.340 11.733 9.635 3.7143 -
Local Peer ILLUMINA INC NASDAQ 48,657.000 58.907 50.007 10.9612 -
Local Peer REGENERON PHARMACEUTICALS INC NASDAQ 39,432.125 16.132 18.390 3.7539 -
Local Peer ALEXION PHARMACEUTICAL INC NASDAQ 24,651.817 317.678 16.767 2.3779 -
Local Peer SEATTLE GENETICS INC NASDAQ 19,143.816 - - 10.7573 -
Local Peer INCYTE CORPORATION NASDAQ 16,904.357 154.388 41.743 6.9780 -
Local Peer BIOMARIN PHARMACEUTICAL NASDAQ 15,733.354 - - 5.1175 -
Local Peer GALAPAGOS NV SPON ADR REPR 1 ORD SHS NASDAQ 15,229.078 - 49.069 5.5099 -
Local Peer ALNYLAM PHARMACEUTICALS INC NASDAQ 12,891.589 - - 8.0217 -
Other Local Peers BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), EXACT SCIENCES CORP (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), 10X GENOMICS INC (NASDAQ), BIONTECH SE SPON ADS EACH REP 1 ORD SHS (NASDAQ), MODERNA INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), EXELIXIS INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), REPLIGEN CORP (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), IMMUNOMEDICS INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), FIBROGEN INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), ALKERMES PLC (NASDAQ), NATERA INC (NASDAQ), ACCELERON PHARMA (NASDAQ), KODIAK SCIENCES INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), UNIQURE N.V. (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), EPIZYME INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), SYNTHORX INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), XENCOR INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), ARVINAS INC (NASDAQ), VIELA BIO INC (NASDAQ), INSMED INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), REGENXBIO INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), CORTEXYME INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), ALECTOR INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), VERACYTE INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), NEXTCURE INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), AVITA MEDICAL LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), OPKO HEALTH INC (NASDAQ), DERMIRA INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), XBIOTECH INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), INTREXON CORP (NASDAQ), RADIUS HEALTH INC (NASDAQ), ACHILLION PHARMACEUTICALS INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), OMEROS CORP (NASDAQ), CYTOKINETICS INC (NASDAQ), AVROBIO INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), IMMUNOGEN INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), RETROPHIN INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), NANTKWEST INC (NASDAQ), ARDELYX INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), MACROGENICS INC (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), KURA ONCOLOGY INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), AGENUS INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), MERUS B V (NASDAQ), TRANSLATE BIO INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), BELLUS HEALTH INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), COMPUGEN (NASDAQ), CABALETTA BIO INC (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), RECRO PHARMA INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), PERSONALIS INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), MINERVA NEUROSCIENCES INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), IVERIC BIO INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), NOVAVAX INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), MEDICINOVA INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), GERON CORP (NASDAQ), KAMADA (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), LIMINAL BIOSCIENCES INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), SERES THERAPEUTICS (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), AFFIMED N V (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), XOMA CORP (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), IMV INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), GLYCOMIMETICS INC (NASDAQ), ATHERSYS INC (NASDAQ), CHIASMA INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), MONOPAR THERAPEUTICS INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), ARAVIVE INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), CONTRAFECT CORP (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), SAVARA INC (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), VERASTEM INC (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), NEUROBO PHARMACEUTICALS INC (NASDAQ), CHIMERIX INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), ADURO BIOTECH INC (NASDAQ), OTONOMY INC (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), SYNLOGIC INC (NASDAQ), COHBAR INC (NASDAQ), SESEN BIO INC (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), INFLARX N V (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), ORGENESIS INC (NASDAQ), TREVENA INC (NASDAQ), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), VERMILLION INC (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), VACCINEX INC (NASDAQ), EQUILLIUM INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), INMUNE BIO INC (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), CURIS INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), RESTORBIO INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), ADVAXIS INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), SOLIGENIX INC (NASDAQ), ZAFGEN INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), EVOGENE LTD (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), CELLDEX THERAPEUTICS INC (NASDAQ), BIOCARDIA INC (NASDAQ), OCUGEN INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), SOPHIRIS BIO INC (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), VAXART INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), ATYR PHARMA INC (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), PRECIPIO INC (NASDAQ), SENESTECH INC (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), CONATUS PHARMACEUTICALS INC (NASDAQ), BIOCEPT INC (NASDAQ), TOCAGEN INC (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), TROVAGENE INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), OPGEN INC (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), BENITEC BIOPHARMA LTD SPON ADS EA REPR 200 ORD SHS(POST SPLIT) (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), SPHERIX INC (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), SENECA BIOPHARMA INC (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ)
Global Peer CSL ASX 139,428.012 51.969 51.969 18.6323 0.864
Global Peer AMGEN-T HKEx 594,184.000 9.032 9.399 6.9364 4.385
Global Peer AGILENT TECHNOLOGIES INC NYSE 27,956.794 88.471 26.103 5.8881 0.678
Global Peer SINO BIOPHARM HKEx 144,849.829 13.518 14.030 4.3138 0.635
Global Peer WUXI BIO HKEx 131,263.877 175.744 137.391 13.5119 -
Global Peer BEIGENE HKEx 101,672.550 - - 10.1444 -
Global Peer Lonza SGX 5,937.453 6.613 6.613 0.6568 4.787
Global Peer GENSCRIPT BIO HKEx 32,753.258 196.970 - 9.2365 -
Global Peer 3SBIO HKEx 27,533.275 18.201 22.153 2.7137 -
Global Peer EMERGENT BIOSOLUTIONS INC NYSE 3,016.907 48.117 701.606 2.9149 -
Other Global Peers HAOHAI BIOTEC (HKEx), ALPHAMAB-B (HKEx), MYOVANT SCIENCES LTD (NYSE), POLYNOVO LIMITED (ASX), FRONTAGE (HKEx), CKLIFE SCIENCES (HKEx), AVITA MEDICAL LTD (ASX), MESOBLAST LTD (ASX), VIVA BIOTECH (HKEx), ASCENTAGE-B (HKEx), KADMON HLDGS INC (NYSE), NANOVIRICIDES INC (NYSE American), SINOMAB BIO-B (HKEx), ARCUS BIOSCIENCES INC (NYSE), ASCLETIS-B (HKEx), ESSEX BIO-TECH (HKEx), LEE'S PHARM (HKEx), DPHARMA (Bursa), NEXT SCIENCE LTD (ASX), TELIX PHARMACEUTIC (ASX), PFENEX INC (NYSE American), BBI LIFE SCI (HKEx), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), NEUREN PHARMACEUTICALS LTD (ASX), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), RESAPP HEALTH LIMITED (ASX), PYC THERAPEUTICS LIMITED (ASX), LINEAGE CELL THERAPEUTICS INC (NYSE American), UNI-BIO GROUP (HKEx), ENZO BIOCHEM INC (NYSE), CEL-SCI CORP (NYSE American), 22ND CENTURY GROUP INC (NYSE American), PALATIN TECHNOLOGIES INC (NYSE American), IMUGENE LIMITED (ASX), CYNATA THERAPEUTICS LTD (ASX), IMMUTEP LTD (ASX), ONCOSIL MEDICAL LIMITED (ASX), SYNTHETIC BIOLOGICS INC (NYSE American), ORTHOCELL LIMITED (ASX), ISORAY INC (NYSE American), CT ENTERPRISE (HKEx), INVEX THERAPEUTICS LTD NPV (ASX), BIOSINO BIO-TEC (HKEx), ANTEOTECH LIMITED (ASX), KAZIA THERAPEUTICS LIMITED (ASX), ARMATA PHARMACEUTICALS INC (NYSE American), IBIO INC (NYSE American), REGENT PACIFIC (HKEx), MEMPHASYS LTD (ASX), BIOTRON (ASX), BIONOMICS LTD (ASX), ACTINOGEN MEDICAL LTD (ASX), GENETIC TECHNOLOGIES (ASX), TALI DIGITAL LIMITED (ASX), EXTRAWELL PHAR (HKEx), ORAGENICS INC (NYSE American), ACTINIUM PHARMACEUTICALS INC (NYSE American), INDIA GLOBALIZATION CAPITAL INC (NYSE American), RHINOMED LIMITED (ASX), CCP TECHNOLOGIES LTD (ASX), PROTEOMICS INTL LABORATORIES LTD (ASX), IMMURON LIMITED (ASX), PATRYS LIMITED (ASX), CELLMID LIMITED (ASX), PRESCIENT THERAPEUTICS LIMITED (ASX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), Suntar Eco-City^ (SGX), REGENEUS LTD (ASX), HOLISTA COLLTECH LIMITED (ASX), ALTERITY THERAPEUTICS LIMITED (ASX), ANATARA LIFESCIENCES LTD (ASX), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), ADALTA LTD (ASX), NOVABAY PHARMACEUTICALS INC (NYSE American), SIENNA CANCER DIAGNOSTICS LTD (ASX), AIM IMMUNOTECH INC (NYSE American), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), BENITEC BIOPHARMA LTD (ASX), BIOXYNE LIMITED (ASX), AUSTRALIAN PRIMARY HEMP LTD (ASX), HAO WEN HLDGS (HKEx), LIVING CELL TECHNOLOGIES (ASX), MEDIBIO LIMITED (ASX), QT Vascular (SGX), MGRC (Bursa), TBG DIAGNOSTICS LTD (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), NANOLLOSE LTD (ASX), AMPLIA THERAPEUTICS LTD (ASX), FACTOR THERAPEUTICS LIMITED (ASX), BPH ENERGY LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.635
-8.43 %
10 Days --1.080
-13.54 %
20 Days --1.920
-21.78 %
Medium Term Return 3 Months -+2.945
+74.56 %
6 Months -+2.305
+50.22 %
1 Year -+2.995
+76.79 %
Long Term Return 2 Years --17.105
-71.27 %
Annualised Return Annualised --
-46.40 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 2.790 - 10.000 Change From 1 Year Low +4.105 % Change From 1 Year Low (%) +147.13
Change From 1 Year High -3.105 % Change From 1 Year High (%) -31.05
2 Years Range 2.660 - 29.250 Change From 2 Years Low +4.235 % Change From 2 Years Low (%) +159.21
Change From 2 Years High -22.355 % Change From 2 Years High (%) -76.43
5 Years Range 2.660 - 29.290 Change From 5 Years Low +4.235 % Change From 5 Years Low (%) +159.21
Change From 5 Years High -22.395 % Change From 5 Years High (%) -76.46
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treat cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

Historical Price Data

Date Open High Low Close Volume VWAP
22 Jan 2020 7.190 7.330 6.850 6.895 293,096 -
21 Jan 2020 7.230 7.300 6.980 7.190 354,340 -
17 Jan 2020 7.530 7.660 7.210 7.240 330,372 -
16 Jan 2020 7.720 8.021 7.397 7.530 420,027 -
15 Jan 2020 7.400 7.767 7.180 7.690 375,799 -
14 Jan 2020 7.080 7.490 6.730 7.440 758,948 -
13 Jan 2020 7.430 7.430 6.930 7.080 652,825 -
10 Jan 2020 8.000 8.162 7.410 7.430 536,115 -
09 Jan 2020 7.690 8.190 7.630 7.975 488,972 -
08 Jan 2020 7.730 7.870 7.470 7.720 652,229 -
07 Jan 2020 7.840 7.890 7.600 7.775 504,859 -
06 Jan 2020 8.110 8.235 7.870 7.910 684,132 -
03 Jan 2020 8.540 8.540 8.083 8.140 751,925 -
02 Jan 2020 8.750 8.960 8.320 8.700 805,169 -
31 Dec 2019 8.100 9.320 7.850 8.730 1,540,230 -
30 Dec 2019 8.500 8.540 8.100 8.115 541,052 -
27 Dec 2019 8.750 8.800 8.090 8.420 885,237 -
26 Dec 2019 9.070 10.000 8.790 8.815 1,049,395 -
24 Dec 2019 8.570 9.250 8.430 8.940 658,400 -
23 Dec 2019 8.330 8.570 8.130 8.360 442,822 -
20 Dec 2019 8.550 8.660 7.950 8.280 1,036,775 -
19 Dec 2019 8.060 8.600 7.950 8.300 840,312 -
Summary
Current 2 Weeks
(08 Jan 2020 to 22 Jan 2020)
7.730 8.190 6.730 6.895 4,862,723 -
Previous 2 Weeks
(23 Dec 2019 to 07 Jan 2020)
8.330 8.570 6.730 7.775 7,863,221 -
4 Weeks from
(22 Nov 2019 to 20 Dec 2019)
4.750 8.190 4.680 8.280 26,689,086 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.